Ipamorelin research: what the human studies actually show

Ipamorelin has two published human studies behind it, and the larger one missed its primary endpoint. The most detailed account of that record is not a marketing page but FDA's own advisory committee file, which counts two deaths among ipamorelin-treated surgical patients, higher rates of low potassium and high blood sugar than placebo, and no safety data at all for the subcutaneous route that most users describe. The compound remains on FDA's category 2 list for outsourcing facilities, and it is not among the peptides covered by the HHS enforcement discretion policy announced on October 30.[1][2][3][4][6]

Reader offer · IQON Labs

Buy 1, Get 1 20% Off

Pick any two research compounds. Take 20% off the lower priced one.

20% OFF

Applied automatically at checkout, no code needed

Claim my 20% off →

In every pair, the lower priced item is 20% off after other discounts; accessories excluded. For research use only.

Research explainer. No dosing, administration or purchase guidance is given, and nothing here is a claim about human benefit for any research product.

A five amino acid secretagogue, and where the selectivity claim comes from

Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. Novo Nordisk researchers described it in 1998 as a growth hormone secretagogue, a compound that prompts the pituitary to release growth hormone through a receptor separate from the growth hormone releasing hormone receptor.[5] FDA's later review describes that target as the ghrelin receptor.[1]

The paper that introduced it also produced the claim that now travels furthest online. In anaesthetised rats and conscious swine, ipamorelin released growth hormone with potency comparable to an older secretagogue, GHRP-6. The difference was in what else moved. GHRP-6 and GHRP-2 raised ACTH, the adrenocorticotropic hormone that signals the adrenal glands to produce cortisol, and they raised cortisol itself. Ipamorelin did not raise either to levels significantly different from control, and none of the secretagogues tested affected follicle-stimulating hormone (FSH) or luteinizing hormone (LH), the two that drive reproductive function, prolactin, or thyroid-stimulating hormone (TSH).[5]

That is a real finding, and it is animal pharmacology. It is the origin of the phrase "clean pulse, no cortisol spike" that appears in peptide forums and on seller pages. The published human studies of ipamorelin measured growth hormone, not a cortisol response, so they neither confirm nor refute the marketing version of the claim.[2][3]

The growth hormone study measured a pulse, not an outcome

The human pharmacokinetic work is small and precise about what it measured. A dose escalation study gave 15 minute intravenous infusions at five dose levels to eight healthy male volunteers at each level. Ipamorelin concentrations rose in proportion to dose, with a terminal half-life of about two hours, and growth hormone rose in a single episode that peaked around 40 minutes and then declined to negligible levels at every dose.[2]

That is the entire human evidence for the central selling point. One pulse of growth hormone, measured over hours, in healthy men. No study in that record measured body composition, sleep quality, recovery, injury healing or fatigue. A rise in a hormone is not the same as a change in any of those, and nothing in the study design could have shown one.[2]

The one trial in patients missed its endpoint

The largest human study of ipamorelin was a multicentre, double blind, placebo controlled phase 2 trial in adults recovering from bowel resection, run under ClinicalTrials.gov identifier NCT00672074. Patients received intravenous ipamorelin at 0.03 mg per kilogram twice daily, or placebo, from the first to the seventh day after surgery or until discharge. The primary endpoint was the time from the first dose to tolerating a standard solid meal.[3]

Median time to that meal was 25.3 hours with ipamorelin and 32.6 hours with placebo, a difference the authors reported as not statistically significant (p = 0.15). One hundred seventeen patients were enrolled and 114 formed the safety and modified intention to treat populations. The authors concluded that ipamorelin was well tolerated and that there were no significant differences from placebo in the key or secondary efficacy analyses.[3]

For a compound sold on the strength of its growth hormone release, that is the only completed test of a clinical outcome in patients, and it is negative. The trial was designed for postoperative ileus rather than for body composition or recovery training, so it cannot rule out effects in other settings. It can be said plainly that no published trial has demonstrated one.

What FDA's reviewers added to the published record

FDA's briefing document for the July 2026 Pharmacy Compounding Advisory Committee meeting goes through the same trial in more detail than the abstract does, and the numbers are worth reading together. Serious adverse events occurred in 10 of 56 ipamorelin patients (17.9%) and 9 of 58 placebo patients (15.5%). Low potassium was reported in 12.5% of the ipamorelin group against 3.4% of the placebo group, insomnia in 10.7% against 5.2%, and high blood sugar at discharge in 14.3% against 8.6%.[1]

Two patients in the ipamorelin group died. Both had undergone bowel resection for colon cancer and developed complications of anastomotic leak, a failure of the surgical join. FDA lists the primary causes as hyperkalemia, a blood potassium level high enough to disturb heart rhythm, in a patient with aortic clots, sepsis, a perforated ulcer and renal failure, and sepsis in a patient with pneumonia. The agency states that it is unclear whether the deaths were related to ipamorelin, and that their occurrence alongside the higher rates of low potassium and high blood sugar raises concern about use in compounding.[1]

The review adds three further problems that no amount of chemistry on a certificate of analysis answers. There are no clinical studies of immunogenicity, the tendency of a peptide product to provoke an immune response, or of aggregation, the tendency of peptide molecules to clump in ways that can trigger one. There is no safety data at all for subcutaneous administration, the route the nomination proposed. Separately, stimulating the growth hormone and IGF-1 axis, where IGF-1 is insulin-like growth factor 1, the hormone the liver produces in response to growth hormone, carries the risks listed in the warnings and precautions of every approved recombinant growth hormone label. Those include glucose intolerance, raised intracranial pressure and fluid retention, and FDA said it had insufficient data to conclude that ipamorelin avoids them. Animal and laboratory studies were too limited in scope and duration, and the agency noted that ghrelin receptor activity could carry reinforcing effects relevant to addiction and reproductive health.[1]

FDA's conclusion was a proposal not to add ipamorelin, in either its free base or acetate form, to the list of bulk substances that can be used in 503A compounding. That is a regulatory judgment about evidence, not a finding of harm in any individual, and the agency said so in its own framing.[1]

Where it stands after the October policy

Ipamorelin acetate has been in category 2 of FDA's interim policy for outsourcing facilities since September 29, 2023. FDA uses that category for bulk substances it considers may present significant safety risks, and its note on ipamorelin cites the immunogenicity risk from aggregation or peptide related impurities, the difficulty of characterising a peptide built from unnatural amino acids, and the published study that recorded serious adverse events including death when the drug was given intravenously for gastric motility.[4]

The HHS enforcement discretion policy announced on October 30 is narrower than headlines suggested, and it does not reach this compound. Its Appendix A names six peptide bulk substances, and the discretion applies only to licensed pharmacies, federal facilities and physicians that meet all ten of the policy's conditions. Ipamorelin is not on that list, and the policy did not add any substance to the 503A bulks list.[6][9]

In Australia the picture is different again. A Victorian coroner found in October 2026 that the actor Richard Norton died of anaphylaxis after injecting a prescribed CJC1295 and ipamorelin blend, and recommended that the Therapeutic Goods Administration consider further restrictions. Our report on that finding sets out what the coroner did and did not determine.[7]

Where the popular claims outrun the record

Search results and forum posts attach a long list of benefits to ipamorelin: better sleep, faster recovery, fat loss, skin quality, injury healing, and a "clean" hormone pulse that leaves stress hormones alone. The published human evidence covers a growth hormone pulse in healthy men and one negative surgical trial. None of the other outcomes appears as an endpoint in either study.[2][3]

User reports are not useless, but they are not evidence of cause. Public threads describe stacks with CJC-1295, weeks of subjective sleep and recovery changes, and adverse reactions that include facial flushing, a racing heartbeat, dizziness and, in one detailed account, a brief loss of consciousness after an injection.[8] Those reports cannot tell a reader whether a product contained the labelled peptide, at what purity, or whether a symptom came from the peptide, an impurity or something else. They are a reason to ask what has actually been measured, which is a short list.

The gap matters most where money changes hands. A certificate of analysis can speak to identity and purity of a batch. It says nothing about whether a peptide produces the effect in the advertisement, and FDA's review is explicit that characterisation, immunogenicity and route specific safety data are all missing for this compound.[1][4] Our explainer on what research use only means covers why a label does not change the regulatory position.

What would change the answer

Three kinds of evidence would move ipamorelin from a plausible mechanism to a supported one. A randomised trial using the subcutaneous route with a clinical endpoint and a safety window long enough to capture immune reactions. Immunogenicity and aggregation testing on the actual compounded formulation. And long term data on growth hormone and IGF-1 exposure, the axis where approved products already carry warnings and precautions about neoplasia, glucose intolerance and fluid retention.[1]

None of those exists in the public record reviewed for this article, and the compounding file that would have created an incentive to generate them closed with a recommendation against listing. Until that changes, the honest summary is the one the evidence supports: a small molecule with an interesting animal profile, two small human studies, one failed endpoint, and a safety file that names the questions nobody has measured.

Frequently asked questions

Is ipamorelin FDA approved?

No. It is not an approved drug for any use. FDA lists ipamorelin acetate in category 2 of its interim policy for outsourcing facilities, which is reserved for bulk substances the agency considers may present significant safety risks, and its advisory committee briefing proposed not adding ipamorelin to the 503A bulks list.

[1] [4]

Does the HHS peptide compounding policy cover ipamorelin?

No. The interim policy announced on October 30, 2026 names six peptide bulk substances in its Appendix A and applies only to licensed pharmacies, federal facilities and physicians that meet all ten of its conditions. Ipamorelin is not on that list, and the policy did not add any substance to the 503A bulks list.

[6] [9]

Does ipamorelin raise cortisol?

The claim that it does not comes from animal work. In swine, ipamorelin did not raise ACTH or cortisol to levels significantly different from control, while GHRP-6 and GHRP-2 did. The published human studies measured growth hormone, not cortisol, so they do not settle the question either way.

[2] [5]

Has ipamorelin been tested for weight loss or sleep?

Not in any published randomised trial reviewed here. The human record consists of a pharmacokinetic study in healthy men and a phase 2 trial in patients recovering from bowel surgery, which measured time to tolerate a meal and found no significant difference from placebo. FDA's review found no data supporting effectiveness by the subcutaneous route for the conditions nominated.

[1] [2] [3]